Arena Pharmaceuticals (NASDAQ:ARNA) was the recipient of a large decline in short interest in January. As of February 14th, there was short interest totalling 59,248,778 shares, a decline of 8.9% from the January 31st total of 65,038,639 shares, Analyst Ratings Network reports. Approximately 27.3% of the shares of the company are short sold. Based on an average daily volume of 5,843,561 shares, the days-to-cover ratio is currently 10.1 days. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) weekly performance is -8.85%. On last trading day company shares ended up $6.49. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)distance from 50-day simple moving average (SMA50) is -3.18%. Analysts mean target price for the company is $8.71.
Investors in Celgene Corporation (NASDAQ:CELG) got a couple of scares Friday when the biotech company’s shares plunged in early trading over concerns that British regulators don’t want to approve use of its Revlimid medication in certain uses and the prospect of an early patent expiration on that same drug. Celgene Corporation (NASDAQ:CELG) shares fell -4.22% in last trading session and ended the day on $149.41. CELG return on equity ratio is recorded as 25.80% and its return on assets is 11.50%. Celgene Corporation (NASDAQ:CELG) yearly performance is 30.74%.
In what’s shaping up as a year of oversized paydays for chief executives, Gilead Sciences, Inc. (NASDAQ:GILD) CEO John Martin has emerged as one of 2013’s biggest winners. Martin pulled in compensation valued at nearly $180 million in 2013, including stock option gains worth $158 million, the biotech giant said Friday. Martin received $15.4 million in salary, incentive awards, stock and stock options — about what he’s made in each of the past three fiscal years. But he cashed in on stock options for a $158.9 million gain and received another $4.8 million from shares that vested last year, Gilead said in a preliminary proxy filing. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved down -3.79% in last trading session and was closed at $75.05, while trading in range of $74.55 – $77.10. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is -0.07%.
CEL-SCI Corporation (NYSE MKT:CVM) announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is 8.51%. On last trading day company shares ended up $1.53. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is 48.63%. Analysts mean target price for the company is $7.00.